Project Details
Description
This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.
| Status | Finished |
|---|---|
| Effective start/end date | 8/10/19 → 23/04/25 |
Collaborative partners
- Merck Sharp & Dohme LLC (lead)
- Pfizer
- Rashid Center for Diabetes and Research
- Thumbay University Hospital
- Gulf Medical University
Keywords
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Sodium-Glucose Transporter 2 Inhibitors
- Molecular Mechanisms of Pharmacological Action
- Metformin
- Ertugliflozin
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.